Molina Healthcare (MOH)
Market Price (5/21/2026): $182.19 | Market Cap: $9.3 BilSector: Health Care | Industry: Managed Health Care
Molina Healthcare (MOH)
Market Price (5/21/2026): $182.19Market Cap: $9.3 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -57% Stock buyback supportStock Buyback 3Y Total is 2.0 Bil Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Health Data Analytics, Telehealth Platforms, Show more. | Weak multi-year price returns2Y Excs Rtn is -87%, 3Y Excs Rtn is -117% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 26x, P/EPrice/Earnings or Price/(Net Income) is 49x Weak revenue growthRev Chg QQuarterly Revenue Change % is -3.1% Key risksMOH key risks include [1] its extreme reliance on government-funded programs, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -57% |
| Stock buyback supportStock Buyback 3Y Total is 2.0 Bil |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Health Data Analytics, Telehealth Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -87%, 3Y Excs Rtn is -117% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 22x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 26x, P/EPrice/Earnings or Price/(Net Income) is 49x |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -3.1% |
| Key risksMOH key risks include [1] its extreme reliance on government-funded programs, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Molina Healthcare (MOH) stock has remained largely at the same level since 1/31/2026 because of the following key factors:
1. Mixed Q1 2026 Earnings Report and Reaffirmed Guidance.
Molina Healthcare reported mixed results for the first quarter of 2026. While the company exceeded adjusted earnings per share (EPS) expectations by 31.28%, posting $2.35 against an estimated $1.79, its revenue of $10.8 billion slightly missed consensus estimates and represented a 3.2% year-over-year decline. Furthermore, GAAP EPS saw a significant drop of 95.1% to $0.27, primarily due to a $93 million impairment charge related to the planned exit of its Medicare Advantage-Part D product for 2027. Despite these varied outcomes, Molina Healthcare reaffirmed its full-year 2026 guidance, projecting approximately $42 billion in premium revenue and adjusted earnings of at least $5.00 per diluted share, which helped stabilize investor sentiment.
2. Medicaid Membership Attrition and Strategic Marketplace Adjustments.
The company experienced a decline in Medicaid membership, attributed to general market contraction and the conclusion of its Medicaid contract in Virginia. This led Molina to increase its forecast for Medicaid attrition to 6% for the full year 2026, up from previous guidance of a 2% decline. To counterbalance this, Molina implemented strategic product and pricing adjustments within its Marketplace segment, with expectations that increased revenue from this area would offset the losses from Medicaid membership, contributing to a relatively steady overall financial outlook.
Show more
1. Mixed Q1 2026 Earnings Report and Reaffirmed Guidance.
Molina Healthcare reported mixed results for the first quarter of 2026. While the company exceeded adjusted earnings per share (EPS) expectations by 31.28%, posting $2.35 against an estimated $1.79, its revenue of $10.8 billion slightly missed consensus estimates and represented a 3.2% year-over-year decline. Furthermore, GAAP EPS saw a significant drop of 95.1% to $0.27, primarily due to a $93 million impairment charge related to the planned exit of its Medicare Advantage-Part D product for 2027. Despite these varied outcomes, Molina Healthcare reaffirmed its full-year 2026 guidance, projecting approximately $42 billion in premium revenue and adjusted earnings of at least $5.00 per diluted share, which helped stabilize investor sentiment.
2. Medicaid Membership Attrition and Strategic Marketplace Adjustments.
The company experienced a decline in Medicaid membership, attributed to general market contraction and the conclusion of its Medicaid contract in Virginia. This led Molina to increase its forecast for Medicaid attrition to 6% for the full year 2026, up from previous guidance of a 2% decline. To counterbalance this, Molina implemented strategic product and pricing adjustments within its Marketplace segment, with expectations that increased revenue from this area would offset the losses from Medicaid membership, contributing to a relatively steady overall financial outlook.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 1.5% change in MOH stock from 1/31/2026 to 5/20/2026 was primarily driven by a 362.1% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 5202026 | Change |
|---|---|---|---|
| Stock Price ($) | 179.59 | 182.24 | 1.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 44,550 | 45,075 | 1.2% |
| Net Income Margin (%) | 2.0% | 0.4% | -79.0% |
| P/E Multiple | 10.7 | 49.3 | 362.1% |
| Shares Outstanding (Mil) | 52 | 51 | 3.1% |
| Cumulative Contribution | 1.5% |
Market Drivers
1/31/2026 to 5/20/2026| Return | Correlation | |
|---|---|---|
| MOH | 1.5% | |
| Market (SPY) | 7.4% | -15.4% |
| Sector (XLV) | -4.5% | 0.2% |
Fundamental Drivers
The 19.1% change in MOH stock from 10/31/2025 to 5/20/2026 was primarily driven by a 442.2% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 5202026 | Change |
|---|---|---|---|
| Stock Price ($) | 153.06 | 182.24 | 19.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 44,550 | 45,075 | 1.2% |
| Net Income Margin (%) | 2.0% | 0.4% | -79.0% |
| P/E Multiple | 9.1 | 49.3 | 442.2% |
| Shares Outstanding (Mil) | 52 | 51 | 3.1% |
| Cumulative Contribution | 19.1% |
Market Drivers
10/31/2025 to 5/20/2026| Return | Correlation | |
|---|---|---|
| MOH | 19.1% | |
| Market (SPY) | 9.3% | -9.9% |
| Sector (XLV) | 2.9% | 7.6% |
Fundamental Drivers
The -44.3% change in MOH stock from 4/30/2025 to 5/20/2026 was primarily driven by a -85.2% change in the company's Net Income Margin (%).| (LTM values as of) | 4302025 | 5202026 | Change |
|---|---|---|---|
| Stock Price ($) | 327.01 | 182.24 | -44.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 41,866 | 45,075 | 7.7% |
| Net Income Margin (%) | 2.8% | 0.4% | -85.2% |
| P/E Multiple | 15.2 | 49.3 | 225.0% |
| Shares Outstanding (Mil) | 55 | 51 | 7.3% |
| Cumulative Contribution | -44.3% |
Market Drivers
4/30/2025 to 5/20/2026| Return | Correlation | |
|---|---|---|
| MOH | -44.3% | |
| Market (SPY) | 35.2% | -1.8% |
| Sector (XLV) | 6.6% | 23.7% |
Fundamental Drivers
The -38.8% change in MOH stock from 4/30/2023 to 5/20/2026 was primarily driven by a -84.2% change in the company's Net Income Margin (%).| (LTM values as of) | 4302023 | 5202026 | Change |
|---|---|---|---|
| Stock Price ($) | 297.89 | 182.24 | -38.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 32,353 | 45,075 | 39.3% |
| Net Income Margin (%) | 2.6% | 0.4% | -84.2% |
| P/E Multiple | 20.0 | 49.3 | 146.3% |
| Shares Outstanding (Mil) | 58 | 51 | 13.0% |
| Cumulative Contribution | -38.8% |
Market Drivers
4/30/2023 to 5/20/2026| Return | Correlation | |
|---|---|---|
| MOH | -38.8% | |
| Market (SPY) | 85.2% | 4.6% |
| Sector (XLV) | 15.8% | 30.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MOH Return | 50% | 4% | 9% | -19% | -40% | 6% | -13% |
| Peers Return | 39% | 4% | -8% | -25% | 4% | 24% | 29% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| MOH Win Rate | 75% | 42% | 58% | 33% | 42% | 40% | |
| Peers Win Rate | 53% | 52% | 42% | 45% | 57% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| MOH Max Drawdown | -17% | -28% | -21% | -34% | -62% | -39% | |
| Peers Max Drawdown | -15% | -20% | -22% | -36% | -41% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CNC, UNH, ELV, CVS, HUM. See MOH Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/20/2026 (YTD)
How Low Can It Go
| Event | MOH | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -12.9% | -6.7% |
| % Gain to Breakeven | 14.9% | 7.1% |
| Time to Breakeven | 29 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.5% | -24.5% |
| % Gain to Breakeven | 25.7% | 32.4% |
| Time to Breakeven | 41 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -29.9% | -33.7% |
| % Gain to Breakeven | 42.7% | 50.9% |
| Time to Breakeven | 16 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -26.8% | -19.2% |
| % Gain to Breakeven | 36.6% | 23.8% |
| Time to Breakeven | 53 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -26.6% | -3.7% |
| % Gain to Breakeven | 36.3% | 3.9% |
| Time to Breakeven | 40 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -37.3% | -12.2% |
| % Gain to Breakeven | 59.4% | 13.9% |
| Time to Breakeven | 700 days | 62 days |
In The Past
Molina Healthcare's stock fell -1.0% during the 2025 US Tariff Shock. Such a loss loss requires a 1.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MOH | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -20.5% | -24.5% |
| % Gain to Breakeven | 25.7% | 32.4% |
| Time to Breakeven | 41 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -29.9% | -33.7% |
| % Gain to Breakeven | 42.7% | 50.9% |
| Time to Breakeven | 16 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -26.8% | -19.2% |
| % Gain to Breakeven | 36.6% | 23.8% |
| Time to Breakeven | 53 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -26.6% | -3.7% |
| % Gain to Breakeven | 36.3% | 3.9% |
| Time to Breakeven | 40 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -37.3% | -12.2% |
| % Gain to Breakeven | 59.4% | 13.9% |
| Time to Breakeven | 700 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -40.0% | -17.9% |
| % Gain to Breakeven | 66.6% | 21.8% |
| Time to Breakeven | 94 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -58.8% | -53.4% |
| % Gain to Breakeven | 142.6% | 114.4% |
| Time to Breakeven | 840 days | 1085 days |
In The Past
Molina Healthcare's stock fell -1.0% during the 2025 US Tariff Shock. Such a loss loss requires a 1.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Molina Healthcare (MOH)
Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments, Medicaid, Medicare, Marketplace, and Other. As of December 31, 2021, the company served the company served approximately 5.2 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 18 states. The company was founded in 1980 and is headquartered in Long Beach, California.
AI Analysis | Feedback
Analogies for Molina Healthcare (MOH):- UnitedHealthcare for government-sponsored health programs.
- Elevance Health (formerly Anthem) for Medicaid and Medicare members.
AI Analysis | Feedback
- Medicaid Managed Care Plans: Molina Healthcare provides comprehensive health coverage and coordinated care services to low-income individuals and families eligible for the Medicaid program.
- Medicare Managed Care Plans: The company offers health insurance plans for seniors and individuals with disabilities who qualify for the Medicare program, often including additional benefits beyond traditional Medicare.
- Marketplace Health Plans: Molina Healthcare provides health insurance options to individuals and families purchasing coverage through state-run health insurance marketplaces.
AI Analysis | Feedback
```htmlMolina Healthcare (MOH) sells primarily to individuals rather than other companies. The company serves the following categories of customers:
- Medicaid Members: Low-income families and individuals who qualify for healthcare services through state Medicaid programs.
- Medicare Members: Individuals, typically seniors and certain disabled individuals, who receive healthcare services through the federal Medicare program.
- Marketplace Members: Individuals who purchase health insurance plans through state-based public health insurance exchanges or marketplaces.
AI Analysis | Feedback
nullAI Analysis | Feedback
Joseph Zubretsky, President and Chief Executive Officer
Joseph Zubretsky has over 35 years of experience in the insurance and financial services sectors. Before joining Molina Healthcare as President and CEO in November 2017, he was President and Chief Executive Officer for The Hanover Insurance Group. He previously held senior executive roles at Aetna, including Chief Executive Officer of its Healthagen Holdings subsidiary. Zubretsky was also a partner at Brera Capital Partners, a global private equity firm, and served as executive vice president of business development and chief financial officer at MassMutual Financial Group. He began his career as an insurance partner at Coopers & Lybrand.
Mark Keim, Senior Executive Vice President and Chief Financial Officer
Mark Keim became Molina Healthcare's Chief Financial Officer in February 2021. He joined the company in January 2018 as Executive Vice President of Strategic Planning, Corporate Development, and Transformation. Keim possesses decades of experience in the managed care and financial services fields, having held significant roles at Aetna and GE Capital. He also built and financed a health analytics company.
James Woys, Senior Executive Vice President and Chief Operating Officer
James Woys leads all of Molina's health plan support functions, encompassing information technology, claims processing, and pharmacy operations. Prior to his tenure at Molina, he served as executive vice president, CFO, and COO at Health Net.
Jeff Barlow, Chief Legal Officer and Corporate Secretary
Jeff Barlow has been with Molina Healthcare since 2004.
Debra Bacon, Executive Vice President, Medicaid
Debra Bacon serves as the Executive Vice President for Medicaid at Molina Healthcare.
AI Analysis | Feedback
Molina Healthcare (MOH) faces several key risks to its business, primarily stemming from its heavy reliance on government-sponsored healthcare programs and the inherent volatility of medical costs. The three most significant risks are:- Medical Cost Inflation and Margin Pressure: Molina Healthcare is highly susceptible to rising medical costs and increased healthcare utilization, which can outpace premium adjustments and compress profit margins. The company has repeatedly revised its earnings guidance downward due to unexpected spikes in healthcare utilization, particularly post-pandemic, leading to higher Medical Care Ratios (MCRs) across its segments (Medicaid, Medicare, and Marketplace). This directly impacts profitability as it means a larger share of premium dollars is being spent on patient care.
- Regulatory and Policy Changes in Government Programs: As a pure-play on government-sponsored health insurance, Molina's business model is significantly exposed to changes in healthcare policies, funding mechanisms, and eligibility criteria for Medicaid, Medicare, and the Affordable Care Act (ACA) marketplaces. Potential tightening of Medicaid eligibility (e.g., redetermination rules, work requirements), changes to ACA subsidies, or shifts in administration could reduce membership and revenue. Furthermore, the company's concentration risk, with a heavy reliance on Medicaid, makes it vulnerable to the loss of major state contracts or adverse changes in state-level reimbursement rates.
- Fraud, Abuse, and Compliance Risks: Operating within a heavily regulated healthcare environment, especially with government programs, exposes Molina Healthcare to substantial compliance risks. These include potential violations of complex regulations such as the False Claims Act, Anti-Kickback Statute, and Stark Law, as well as issues related to billing and coding practices, data privacy (HIPAA), and overall regulatory adherence. Non-compliance can lead to severe financial penalties, recoupment demands, legal actions, reputational damage, and even the termination of participation in federal healthcare programs.
AI Analysis | Feedback
nullAI Analysis | Feedback
Molina Healthcare, Inc. operates within the United States, providing managed healthcare services across three primary addressable markets: Medicaid, Medicare, and the state insurance marketplaces. The estimated addressable market sizes for Molina Healthcare's main products or services in the U.S. are as follows: * Medicaid: As of November 2025, approximately 68.8 million people were enrolled in Medicaid across the 50 states and the District of Columbia. * Medicare: The total Medicare market in the U.S. included an estimated 62 million residents in 2023 and 2025. Within this, Medicare Advantage enrollment reached 34.1 million beneficiaries in 2025, representing 54% of all eligible Medicare individuals. * ACA Marketplace: Affordable Care Act (ACA) Marketplace enrollment reached a record high of 24.3 million people in 2025. This figure includes plan selections through the end of the open enrollment period for 2025 coverage.AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Molina Healthcare (MOH) over the next 2-3 years:
- Significant Medicaid Contract Wins and Reprocurements: Molina Healthcare anticipates substantial revenue growth from new and renewed state Medicaid contracts. A notable example is the historic RFP win in Florida for the Children's Medical Services (CMS) contract, projected to generate $6 billion in annual premium revenue starting in late 2026. The company also maintains a robust pipeline of $50 billion in new opportunities over the coming years and boasts high win rates on both renewal and new contracts.
- Targeted Medicare Growth with a Focus on Dual-Eligible Members: Molina is strategically shifting its focus within the Medicare segment to prioritize dual-eligible members, with plans to exit the traditional Medicare Advantage Prescription Drug (MAPD) product by 2027. This move is designed to concentrate growth in a segment offering potentially higher value, building on previous expansions such as the acquisition of Bright Health's California Medicare Advantage units.
- Strategic "Tuck-in" Acquisitions: The company plans to pursue accretive "tuck-in" acquisitions of regional Medicaid plans, behavioral health assets, and duals capabilities. Molina has allocated $1 billion to $3 billion for cumulative mergers and acquisitions capacity over the next 12-24 months, aimed at expanding its membership base and diversifying revenue streams.
AI Analysis | Feedback
Share Repurchases
- Molina Healthcare reported annual share buybacks of $1 billion in both 2025 and 2024.
- A new share repurchase program, authorized up to $1 billion through December 2026, was announced in August 2025 and was partially funded by a new $500 million term loan.
- Between July 1, 2025, and September 30, 2025, the company repurchased 2,849,000 shares for approximately $499.99 million under a program announced on April 24, 2025.
Share Issuance
- Molina Healthcare's shares outstanding declined by 8.32% in 2025 to 0.053 billion, following a 0.69% decline in 2024 and a 0.68% decline in 2023, indicating net share repurchases over issuances.
Inbound Investments
- Cobalt Capital Management initiated a new stake in Molina Healthcare, acquiring 115,000 shares valued at approximately $22.01 million in November 2025.
- Union Square Park Capital Management LLC purchased 10,000 shares, valued at approximately $1.914 million, during the third quarter of 2025.
Outbound Investments
- Molina Healthcare acquired ConnectiCare for $350 million in July 2024.
- The company has expanded its market presence through strategic acquisitions, including Bright Health Medicare and ConnectiCare, and continues to eye additional opportunities.
- Net spending on acquisitions was approximately $344 million in 2024.
Capital Expenditures
- Capital expenditures were approximately $101 million in 2025, $100 million in 2024, and $84 million in 2023.
- Consistent capital expenditures, such as $100 million in 2024, reflect the company's commitment to future growth.
Latest Trefis Analyses
Trade Ideas
Select ideas related to MOH.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 243.17 |
| Mkt Cap | 61.8 |
| Rev LTM | 199,258 |
| Op Inc LTM | 6,108 |
| FCF LTM | 6,781 |
| FCF 3Y Avg | 3,938 |
| CFO LTM | 7,774 |
| CFO 3Y Avg | 4,902 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.6% |
| Rev Chg 3Y Avg | 10.5% |
| Rev Chg Q | 4.4% |
| QoQ Delta Rev Chg LTM | 1.0% |
| Op Inc Chg LTM | -56.6% |
| Op Inc Chg 3Y Avg | -14.0% |
| Op Mgn LTM | 2.0% |
| Op Mgn 3Y Avg | 3.2% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 3.2% |
| CFO/Rev 3Y Avg | 2.5% |
| FCF/Rev LTM | 2.5% |
| FCF/Rev 3Y Avg | 2.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 61.8 |
| P/S | 0.3 |
| P/Op Inc | 18.1 |
| P/EBIT | 17.7 |
| P/E | 30.6 |
| P/CFO | 13.3 |
| Total Yield | 4.8% |
| Dividend Yield | 1.5% |
| FCF Yield 3Y Avg | 5.2% |
| D/E | 0.4 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 23.5% |
| 3M Rtn | 30.9% |
| 6M Rtn | 29.3% |
| 12M Rtn | 9.5% |
| 3Y Rtn | -13.0% |
| 1M Excs Rtn | 16.0% |
| 3M Excs Rtn | 19.8% |
| 6M Excs Rtn | 14.8% |
| 12M Excs Rtn | -12.2% |
| 3Y Excs Rtn | -94.6% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Medicaid | 30,579 | 26,327 | 25,783 | 21,231 | 15,217 |
| Medicare | 5,542 | 4,179 | 3,824 | 3,379 | 2,529 |
| Marketplace | 2,506 | 2,023 | 2,296 | 3,091 | 1,677 |
| Other operating revenues | 1,942 | 1,467 | |||
| Other | 81 | 76 | 71 | 70 | |
| Total | 40,650 | 34,072 | 31,974 | 27,771 | 19,423 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Medicaid | 2,979 | 2,973 | 2,981 | 2,322 | |
| Other operating revenues | 1,942 | 1,467 | 1,020 | 846 | |
| Marketplace | 617 | 499 | 290 | 399 | |
| Medicare | 603 | 388 | 437 | 430 | |
| Other | 8 | 9 | 11 | 14 | |
| Other operating expenses | -4,442 | -3,763 | -3,566 | -2,991 | |
| Total | 1,707 | 1,573 | 1,173 | 1,020 |
Price Behavior
Price Behavior
| Market Price | $182.24 | |
| Market Cap ($ Bil) | 9.3 | |
| First Trading Date | 07/02/2003 | |
| Distance from 52W High | -44.1% | |
| 50 Days | 200 Days | |
| DMA Price | $161.38 | $165.79 |
| DMA Trend | down | up |
| Distance from DMA | 12.9% | 9.9% |
| 3M | 1YR | |
| Volatility | 49.2% | 59.2% |
| Downside Capture | -138.25 | -13.52 |
| Upside Capture | -7.41 | -78.42 |
| Correlation (SPY) | 3.6% | -2.9% |
MOH Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.59 | 0.46 | -0.69 | -0.32 | -0.06 | 0.15 |
| Up Beta | 0.52 | 0.67 | -2.01 | -1.72 | -0.19 | 0.26 |
| Down Beta | -4.13 | 1.51 | 0.46 | 0.62 | 0.57 | 0.06 |
| Up Capture | 117% | 60% | -47% | 2% | -29% | -0% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 17 | 24 | 35 | 72 | 134 | 394 |
| Down Capture | -1258% | -30% | -53% | -34% | 13% | 41% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 5 | 19 | 29 | 53 | 117 | 358 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MOH | |
|---|---|---|---|---|
| MOH | -42.6% | 59.2% | -0.69 | - |
| Sector ETF (XLV) | 11.5% | 14.7% | 0.52 | 20.8% |
| Equity (SPY) | 26.2% | 12.1% | 1.62 | -3.2% |
| Gold (GLD) | 40.2% | 26.8% | 1.24 | -3.5% |
| Commodities (DBC) | 46.2% | 18.7% | 1.89 | -0.1% |
| Real Estate (VNQ) | 11.1% | 13.4% | 0.54 | 10.3% |
| Bitcoin (BTCUSD) | -27.4% | 41.8% | -0.65 | -11.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MOH | |
|---|---|---|---|---|
| MOH | -6.7% | 39.6% | -0.06 | - |
| Sector ETF (XLV) | 5.4% | 14.6% | 0.19 | 37.4% |
| Equity (SPY) | 14.1% | 17.0% | 0.65 | 16.3% |
| Gold (GLD) | 19.5% | 18.0% | 0.89 | -2.1% |
| Commodities (DBC) | 11.1% | 19.4% | 0.46 | 2.5% |
| Real Estate (VNQ) | 4.0% | 18.8% | 0.11 | 21.2% |
| Bitcoin (BTCUSD) | 9.1% | 55.6% | 0.37 | 3.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MOH | |
|---|---|---|---|---|
| MOH | 14.9% | 40.6% | 0.48 | - |
| Sector ETF (XLV) | 9.6% | 16.5% | 0.47 | 45.6% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 31.7% |
| Gold (GLD) | 13.1% | 16.0% | 0.68 | -0.9% |
| Commodities (DBC) | 7.9% | 17.9% | 0.36 | 10.0% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 30.1% |
| Bitcoin (BTCUSD) | 67.1% | 66.9% | 1.06 | 2.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/22/2026 | 14.2% | 28.4% | |
| 2/5/2026 | -25.5% | -28.3% | -17.4% |
| 10/22/2025 | -17.5% | -17.9% | -31.1% |
| 7/7/2025 | -2.7% | -7.3% | -33.8% |
| 4/23/2025 | -5.5% | -1.5% | -6.7% |
| 2/5/2025 | -10.1% | -15.9% | 3.3% |
| 10/23/2024 | 17.7% | 17.9% | 7.7% |
| 7/24/2024 | 12.3% | 18.2% | 19.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 15 | 13 |
| # Negative | 15 | 10 | 11 |
| Median Positive | 5.5% | 7.3% | 7.1% |
| Median Negative | -2.7% | -6.2% | -7.7% |
| Max Positive | 17.7% | 28.4% | 19.1% |
| Max Negative | -25.5% | -28.3% | -33.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/23/2026 | 10-Q |
| 12/31/2025 | 02/10/2026 | 10-K |
| 09/30/2025 | 10/23/2025 | 10-Q |
| 06/30/2025 | 07/24/2025 | 10-Q |
| 03/31/2025 | 04/24/2025 | 10-Q |
| 12/31/2024 | 02/11/2025 | 10-K |
| 09/30/2024 | 10/24/2024 | 10-Q |
| 06/30/2024 | 07/25/2024 | 10-Q |
| 03/31/2024 | 04/25/2024 | 10-Q |
| 12/31/2023 | 02/13/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/27/2023 | 10-Q |
| 03/31/2023 | 04/27/2023 | 10-Q |
| 12/31/2022 | 02/13/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| 06/30/2022 | 07/28/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 4/22/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Premium Revenue | 42.00 Bil | -0.5% | Lowered | Guidance: 42.20 Bil for 2026 | |||
| 2026 GAAP EPS | 1.9 | -40.6% | Lowered | Guidance: 3.2 for 2026 | |||
| 2026 Adjusted EPS | 5 | 0 | Affirmed | Guidance: 5 for 2026 | |||
Prior: Q4 2025 Earnings Reported 2/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Premium Revenue | 42.20 Bil | -0.7% | Lower New | Actual: 42.50 Bil for 2025 | |||
| 2026 Total Revenue | 44.50 Bil | 0 | Same New | Actual: 44.50 Bil for 2025 | |||
| 2026 GAAP Net Income | 164.00 Mil | -74.0% | Lower New | Actual: 630.00 Mil for 2025 | |||
| 2026 Adjusted Net Income | 256.00 Mil | -65.5% | Lower New | Actual: 742.00 Mil for 2025 | |||
| 2026 GAAP EPS | 3.2 | -73.1% | Lower New | Actual: 11.9 for 2025 | |||
| 2026 Adjusted EPS | 5 | -64.3% | Lowered | Guidance: 14 for 2026 | |||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hebert, Maurice | Chief Accounting Officer | Direct | Sell | 5152026 | 191.55 | 600 | 114,930 | 2,454,713 | Form |
| 2 | Barlow, Jeff D | Chief Legal Officer | Direct | Sell | 5132026 | 186.12 | 17,811 | 3,314,983 | 12,502,611 | Form |
| 3 | Romney, Ronna | Held by trust | Sell | 3132026 | 146.92 | 506 | 74,342 | 2,530,991 | Form | |
| 4 | Zoretic, Richard C | Held by trust | Buy | 2122026 | 125.16 | 800 | 100,128 | 1,094,775 | Form | |
| 5 | Schapiro, Richard M | Direct | Sell | 11242025 | 143.02 | 357 | 51,058 | 1,623,563 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.